Genetically Driven, Precision Therapy
A Novel Approach for Autoimmune Disease
ABS is addressing one of the most critical unmet needs in autoimmune disease
For 30-50% of patients with inadequate response to standard
of care treatment
ABS is developing precision therapies to normalize or ”reset” the immune system of patients whose genetics make them resistant to successful treatment.
ABS is targeting genetically elevated soluble IL7 receptor likely to be the root cause of refractory disease
ABOUT
Next-Generation, Immuno-Corrective Therapy for Treatment of Autoimmune Diseases by Targeting a Novel, Fundamental Autoimmune Pathway Driven by Upregulation of the Soluble Interleukin 7 Receptor (sIL7R).
Autoimmunity BioSolutions (ABS) is developing a next-generation, immuno-corrective therapy to restore normal immune function in a genetically-defined subpopulation of autoimmune disease patients in which the autoimmune pathology is driven by a SNP that enhances the expression of sIL7R.
OUR VISION
Innovative treatment for the Genetically-Defined Risk Population in Multiple Autoimmune Diseases.
By targeting soluble IL7 receptor (sIL7R) a novel pathway fundamental to immune regulation, ABS is developing precision therapies for patients of various autoimmune diseases defined by the presence of the SNP and high levels of sIL7R.
OUR MISSION
ABS’s mission is to develop therapeutics and biomarkers to dramatically improve outcomes with genetically targeted precision therapies
ABS mAbs and ASOs reduce sIL7R in the risk population
ABS biomarkers seek to identify responder populations for current or emerging standards of care
OUR MISSION
Delivering this Immuno-Corrective Therapy to Patients in Great Need of Improved Treatments.
ABS is committed to provide patients with an effective immuno-corrective therapy that bypasses the safety liabilities associated with immunosuppression.
